Please use this identifier to cite or link to this item:
標題: Synthesis and in vitro evaluation of the phenylboric acid derivative entrapped lipiodol in boron neutron capture therapy for hepatoma
作者: Chou, F.I.
Chung, H.P.
Shieh, M.S.
Huang, C.W.
Chung, R.J.
Liu, H.M.
Yang, J.Y.
Chi, C.W.
Lin, Y.C.
Lu, W.Y.
Ka, J.J.
關鍵字: hepatoma;neutron capture therapy;PBAD-lipiodol;alpha track;hepatocellular-carcinoma;arterial chemoembolization;sodium;borocaptate;enhanced survival;liver-tumors;boronophenylalanine;melanoma;delivery;cancer;chemistry
Project: Anticancer Research
期刊/報告no:: Anticancer Research, Volume 23, Issue 5A, Page(s) 3955-3963.
Background: Hepatoma, a common cancer in Taiwan. responds poorly to conventional therapies. Boron neutron capture therapy (BNCT) may provide a promising approach for hepatoma therapy. In this study, a pharmaceutical composition, phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol), was synthesized and characterized. In vitro study was used for evaluation of PRAD-lipiodol for the BNCT of hepatoma. Materials and Methods: a Track observation was used to identify the boron compound in the TLC plate and to evidence the uniform distribution of boron in the PBAD-lipiodol. Inductively coupled plasma-atomic emission spectroscopy and neutron activation analysis were used to determine the concentrations of boron and lipiodol, respectively. Human hepatoma HepG2 cells were used for in vitro experiments. A Nomarski optical microscope was used to investigate the uptake of PBAD-lipiodol globules in individual hepatoma cells. Results: PBAD-lipiodol was stable in human serum. The boron source, PBAD, was uniformly distributed in PBAD-lipiodol. Many of the PBAD-lipiodol globules were internalized and retained in HepG2 cells, and the boron concentration of HepG2 cells reached 269 ppm after 72 hours of PBAD-lipiodol treatment. Conclusion: In vitro studies revealed that PBAD-lipiodol could deliver a therapeutically effective amount of PBAD as a boron source for the BNCT of hepatoma. PBAD-lipiodol is a potential new boron drug for the BNCT of hepatoma.
ISSN: 0250-7005
Appears in Collections:期刊論文

Show full item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.